[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.137.239. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 27, 2006

Ten vs Five Years of Bisphosphonate Treatment for Postmenopausal OsteoporosisEnough of a Good Thing

Author Affiliations
 

Author Affiliations: Duke University Medical Center, Durham, NC.

JAMA. 2006;296(24):2968-2969. doi:10.1001/jama.296.24.2968

In the 10 years since the first results from the Fracture Intervention Trial (FIT) were published,1,2 it has been relatively straightforward to know when to start bisphosphonate therapy for women with postmenopausal osteoporosis. Clear fracture reduction benefit was shown for women with prior vertebral fracture or bone mineral density (BMD) T scores of −2.5 or lower. However, the issue of when to stop bisphosphonate therapy is less clear, and clinical practice guidelines have been almost completely silent on this important decision point.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×